Under Sanpower, Can Provenge Finally Have A Happy Ending?

 
• By Emily Hayes

Strategy of focusing immunotherapy on urologists and earlier stage prostate cancer is paying off, says CEO James Caggiano, as Dendreon becomes a standalone company under Chinese conglomerate Sanpower

China card
Chinese conglomerate is Dendreon's latest owner • Source: Shutterstock

More from Deals

More from Business